Oct. 1 at 1:33 PM
Wellgistics Health (Nasdaq
$WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, has announced a strategic partnership with TheracosBio to expand nationwide, PBM-free access to Brenzavvy® (bexagliflozin)—an FDA-approved diabetes therapy.
Through its maker-to-taker platform, Wellgistics Health will deliver Brenzavvy directly to patients via a network of 6,500+ independent and chain pharmacies, bypassing costly intermediaries and lowering out-of-pocket expenses for millions living with Type 2 diabetes.
With over 37 million Americans affected by diabetes, this collaboration addresses an urgent healthcare need by making treatment more accessible, affordable, and effective. 🔗 Read more here: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/wellgistics-health-nasdaq-wgrx-and-theracosbio-partner-to-expand-nati-1079815
Skyline is paid by
$WGRX for IR services. Disclaimer 17(b): http://skylineccg.com/disclosures/